UK-based Synairgen on Monday announced positive results from a clinical trial of SNG001, which helped reduce the risk of developing severe diseases in COVID-19 patients
Andrei Kelin said since AstraZeneca already had manufacturing agreement with a Russian company, it made "no sense" to hack COVID-19 vaccine research data
The Spanish dermatologists, who conducted the study, believe enanthem or mouth rash is difficult to notice as COVID-19 patients do not get an oral exam owing to safety concerns